NCT06236672Completed
Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease
Impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Compared to Basal Insulin Start on Metabolic Targets in Patients Living With Type 2 Diabetes and Chronic Kidney Disease (Impact GLP-1 CKD)
Source: ClinicalTrials.gov · Last updated 1 Feb 2024
Brief summary (registry, in English)
The overall objective of this study is to compare the effectiveness of adding a glucagon-like peptide-1 receptor agonist compared with adding basal insulin for patients with type 2 diabetes and chronic kidney disease, already treated with an sodium-glucose cotransporter-2 inhibitor and not currently reaching target glycemic control. All sociodemographic information and clinical variables will be retrieved from the LMC Diabetes Registry.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 348 (actual)
- First submitted
- 23 Jan 2024
- Start date
- 15 Feb 2023
- Primary completion date
- 29 Nov 2023
- Lead sponsor
- LMC Diabetes & Endocrinology Ltd.
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT06236672
What you commit to
- Study type: Observational
- Participants enrolled: 348
- From 15 Feb 2023 to the primary completion date, 29 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Initiation of a second AHA therapy on the index date together with GLP-1RA
- Previous use of any GLP-1 RA therapy
- Previous use of basal and bolus insulin therapy
- Participation in a research study with an Investigational Product
Other illness
- Clinical diagnosis of type 1 diabetes (T1D)
- Documented history or family history of Medullary Thyroid Carcinoma or Multiple Endocrine Neoplasia type 2
- Hypersensitivity to GLP-1 RA or any product component
Lab values
- Most recent eGFR ≤ 15 ml/min/1.73 m2
Who the study is looking for
- 18 years or older as of the index date
- Clinical diagnosis of T2D ≥ one year
- Diagnosis of CKD (defined by Diabetes Canada guideline) with eGFR 15-59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 with the uACR ≥ 2mmol/L
- Use of any SGLT2i for more than 6 months
- Baseline HbA1c ≥7.5%
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| LMC Diabetes & Endocrinology Ltd. Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.